Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers. It needs next generation innovation and growth in emerging markets to keep ahead of competitors ...

There's no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes ... according to Novo Nordisk. "Up to 85% of the materials in every pen ...

Stocks are pricey—but there are values to be had. Learn more about our panelists’ picks in this week’s Roundtable installment.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Novo Nordisk has been able to capitalize from a sad trend as the global diabetes patients have quadrupled from 1990 to 2024. Experts expect this trend to continue as they predict another increase ...

Novo Nordisk (NVO) announced Friday that its popular ... The trial involving more than 1,400 obese adults without diabetes reached its primary endpoint as semaglutide 7.2 mg caused a statistically ...

Novo Nordisk is facing serious pressure from a ... thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity. For the company to continue to grow at the ...

Novo Nordisk Call and Put Volume: 30-Day Overview With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world.

including Novo Nordisk's (NVO) blockbuster GLP-1s. Novo traded 4% lower on the news Friday. Diabetes drug Ozempic and weight-loss drug Wegovy top the list, along with a number of others like Merck ...

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... with the company's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy among the 15 drugs targeted for Medicare ...

Taking aim at the sky-high price of semaglutide, Medicare plans to negotiate prices for Novo Nordisk products Ozempic (an injection to control diabetes), Wegovy (an injection more designed for ...

It hasn't been a great period for investors in Novo Nordisk (NYSE ... of potent drugs for cardiometabolic illnesses like diabetes and obesity. For the company to continue to grow at the same ...